Mirum Shares Rise 3.3% After Livmarli Meets Phase 3 Primary Endpoint
Mirum Pharmaceuticals said Livmarli (maralixibat) met the primary endpoint in a trial treating cholestatic pruritus in certain patients with liver diseases. Shares rose 3.3% to $61.05 in premarket trading Monday.